- Home
- NSTS vs NRXP Comparison
NSTS vs NRXP Comparison
Compare NSTS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | NRXP |
|---|---|---|
| Founded | 1921 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 54.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NSTS | NRXP |
|---|---|---|
| Price | $12.37 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 2.2K | ★ 493.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $256,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.73 | $1.58 |
| 52 Week High | $13.06 | $3.84 |
Technical Indicators
Market Signals| Indicator | NSTS | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 47.54 |
| Support Level | $11.91 | $1.65 |
| Resistance Level | $12.30 | $1.99 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 19.73 | 53.97 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.